Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Isentress vs. Selzentry

Isentress vs. Selzentry

Isentress raltegravir
Trial Dosing Efficacy data
Ph III (018 and 019), n=699 treatment- experienced 400 mg bid, combo w/OBT HIV RNA <50 copies/mL: 61.3% vs. 34.6% for placebo at 16 wks; 62.6% vs. 33.3% at 24 wks

Read the full 400 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers